Article Text

Letters
Abnormal retinal thickening is a common feature among patients with ARSACS-related phenotypes
  1. Patrick Yu-Wai-Man1,2,
  2. Angela Pyle1,
  3. Helen Griffin1,
  4. Mauro Santibanez-Korev1,
  5. Rita Horvath1,3,
  6. Patrick F Chinnery1,3
  1. 1 Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK
  2. 2 Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, UK
  3. 3 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, UK
  1. Correspondence to Dr Patrick Yu-Wai-Man, Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK; Patrick.Yu-Wai-Man{at}ncl.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Autosomal-recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) was first described among French Canadian patients from Québec presenting with a stereotypical triad of early-onset cerebellar ataxia, spastic paraplegia and peripheral neuropathy. Two recurring pathogenic mutations in the SACS gene were subsequently identified in these families in keeping with a mutational founder event in a geographically isolated population.1 However, ARSACS is being increasingly recognised worldwide as an important cause of inherited ataxia.2 Interestingly, non-Québec patients can show strikingly variable features marked by a lack of spasticity, cognitive impairment and a delayed age of onset.2 Given the heterogeneous clinical picture that can be associated with SACS mutations, the identification of ancillary features linked with these genetic defects could prove particularly useful in prioritising the most appropriate lines of investigations when confronted with a suspected case of ARSACS. Although prominent retinal hypermyelination is thought to be a characteristic manifestation of classical ARSACS among Québec patients, this ophthalmological finding has only been described infrequently in patients from Europe, Asia and the Middle East.2 A recent case report has even further argued that retinal ‘hypermyelination’ in ARSACS is a pathologically misleading term that should be …

View Full Text

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement: